Literature DB >> 27402487

Oral Bioavailability and Mass Balance Studies of a Novel Anti-arrhythmic Agent Sulcardine Sulfate in Sprague-Dawley Rats and Beagle Dogs.

You-Li Lu1, Shui-Jun Li1, Gang-Yi Liu1, Xiao-Chuan Li2, Ding Yang3, Jing-Ying Jia1, Meng-Qi Zhang1, Hong-Chao Zheng1, Chen Yu1, Fu Zhu1, Yi-Ping Wang4.   

Abstract

BACKGROUND AND OBJECTIVES: Sulcardine sulfate is a newly developed candidate drug used to control arrhythmias. The aim of this research was to investigate the pharmacokinetics, bioavailability and excretion characteristics of sulcardine in animals.
METHODS: Sprague-Dawley rats were orally and intravenously given sulcardine at 20 and 40 mg/kg. Beagle dogs were also orally and intravenously dosed at 10 mg/kg. Both [3H]-labeled sulcardine and unlabeled sulcardine were given to rats. Feces, urine and bile were collected at 0-72 h for mass balance study. The contents of unlabeled sulcardine and radioactivity in samples were determined by a validated LC-MS/MS method and by liquid scintillation counting, separately.
RESULTS: Sulcardine was rapidly eliminated in rats after dosing. The oral bioavailability was 34-35 % in rats, while a higher exposure was observed in dogs (bioavailability = 62.7 %). More than 90 % of dosed sulcardine was recovered, and approximately 20-40 % of the dose excreted into urine as the original form, and the remaining was found in feces and bile, most of which (about 40 %) was transformed into metabolites. No difference was observed between sexes. Metabolism may occur to a large extent after oral administration in rats but to a smaller extent in dogs.
CONCLUSIONS: Sulcardine was extensively absorbed in both rats and dogs after oral administration. The mass balance data indicated that sulcardine was widely metabolized in rats after oral administration.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27402487     DOI: 10.1007/s13318-016-0360-3

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  7 in total

1.  State-dependent blockade of human ether-a-go-go-related gene (hERG) K(+) channels by changrolin in stably transfected HEK293 cells.

Authors:  Wei-hai Chen; Wen-yi Wang; Jie Zhang; Ding Yang; Yi-ping Wang
Journal:  Acta Pharmacol Sin       Date:  2010-08       Impact factor: 6.150

2.  [The effects of infusion rate of Changrolin on drug concentration in blood and ECG (author's transl)].

Authors:  Z X Qu; C Y Cao; Y H Zhuang
Journal:  Yao Xue Xue Bao       Date:  1980-08

3.  Electrophysiological effects of changrolin, an anti-arrhythmic agent derived from Dichroa febrifuga, on guinea-pig and rabbit heart cells.

Authors:  L L Lu; Y Habuchi; H Tanaka; J Morikawa
Journal:  Clin Exp Pharmacol Physiol       Date:  1995-05       Impact factor: 2.557

4.  Discovery of N-(3,5-bis(1-pyrrolidylmethyl)-4-hydroxybenzyl)-4-methoxybenzenesulfamide (sulcardine) as a novel anti-arrhythmic agent.

Authors:  Dong-Lu Bai; Wei-Zhou Chen; Yun-Xin Bo; Yue-Li Dong; Ai-Li Kang; Wei-Kang Sun; Wei Wang; Zhong-Liang Hu; Yi-Ping Wang
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

5.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

6.  Liquid chromatography/tandem mass spectrometry for the determination of changrolin in rat plasma: application to a bioavailability study.

Authors:  Ding Yang; Chen Yu; Shuijun Li; Gangyi Liu; Youli Lu; Yiping Wang
Journal:  J Pharm Biomed Anal       Date:  2009-04-17       Impact factor: 3.935

7.  Studies on a new antiarrhythmic drug changrolin-4-(3',5'-bis [(N-pyrrolidinyl) methyl]-4'-hydroxyanilino)-quinazoline.

Authors:  L Q Li; Z X Qu; Z M Wang; Y L Zeng; G S Ding; G J Hu; X Y Yang
Journal:  Sci Sin       Date:  1979-10
  7 in total
  1 in total

Review 1.  Seaweed Components as Potential Modulators of the Gut Microbiota.

Authors:  Emer Shannon; Michael Conlon; Maria Hayes
Journal:  Mar Drugs       Date:  2021-06-23       Impact factor: 5.118

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.